ClinicalTrials.gg
CompletedNCT02094261AURA2Updated Nov 6, 2024Results posted

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

A Phase 2 interventional study of AZD9291 in Non Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 44 sites in 8 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 90
210 · median 51
Started
2014
with 9 others
Phase 2
46 of 90
12 open now
Registered
2nd of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is one of 10 that started in 2014, is one of 46 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive

Read the detailed description

This is a phase II, open label, single arm study assessing the safety and efficacy of AZD9291 (80 mg, orally, once daily) in patients with a confirmed diagnosis of Epidermal Growth Factor Receptor mutation positive and T790M mutation positive NSCLC,who have progressed following prior therapy with an approved Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) agent. Patients must agree to provide a biopsy for central confirmation of T790M mutation status following confirmed disease progression on the most recent treatment regimen. The primary objective of the study is to assess the efficacy of AZD9291 by assessment of Objective Response Rate according to RECIST 1.1 by an Independent Central Review.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Phase II, open label study; safety and efficacy of AZD9291; diagnosis of Epidermal Growth Factor Receptor mutation positive and T790M mutation positive NSCLC
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged at least 18 years. Japan patients aged at least 20 years.
  • Locally advanced/ NSCLC not amenable to curative surgery or radiotherapy
  • Radiological documentation of disease progression:

following EGFR TKI treatment but who have not received further treatment OR following prior therapy with an EGFR TKI and a platinum-based doublet chemotherapy. Patients who received prior EGFR TKI and platinum-based doublet chemotherapy may have also received additional lines of treatment. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.

  • Disease progression following 1st line EGFR TKI treatment or following prior EGFR TKI and platinum-containing doublet chemotherapy.
  • Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q). Patients must have central confirmation of tumour T790M mutation positive status from a sample taken after confirmation of disease progression on the most recent treatment regimen.
  • World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
  • At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements.
  • Females of using ; negative pregnancy test.

Exclusion criteria

Exclusion:

  • Treatment with an EGFR-TKI within 8 days of study entry; any cytotoxic chemotherapy, agents or other anticancer drugs within 14 days of study entry; previous treatment with AZD9291 (or 3rd generation TKIs); major surgery within 4 weeks; radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks; current treatment with potent inhibitors of CYP2C8 and potent inhibitors/inducers of .
  • Unresolved toxicities from prior therapy.
  • Unstable spinal cord compression/.
  • Severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding diatheses or infection.
  • nausea/vomiting, chronic gastrointestinal diseases or bowel resection.
  • Cardiac disease.
  • Past history of ILD, drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease.
  • Inadequate bone marrow reserve or organ function.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    AZD9291

    Once daily tablet 80 mg

    Drug: AZD9291

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

    Time frame: RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)

Secondary outcomes

  1. Duration of Response (DoR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).

    Time frame: RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)

  2. Disease Control Rate (DCR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD (according to independent review), prior to progression (PD) or further anti-cancer therapy.

    Time frame: RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)

  3. Progression-Free Survival (PFS)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.

    Time frame: RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)

07

Results

Posted Jun 7, 2016

Participant flow

First patient enrolled: 28 April 2014, Data cut off: 1 May 2015. The study was open for enrolment at 44 study centres in Canada (3), Hong Kong (2), Italy (5), Japan (14), South Korea (3), Spain (6), Taiwan (2), and the USA (9). Recruitment has closed and primary analyses have been performed but study is still on-going.

Participant flow — Overall Study
MilestoneAZD9291 80mg
Started210
Completed0
Not completed210
Withdrew: Death24
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject4
Withdrew: Ongoing study at data cut-off181

Outcome measures

PrimaryObjective Response Rate (ORR)

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

Time frame:
RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)
Reported as:
Number · % of participants
Objective Response Rate (ORR)
% of participantsAZD9291 80mg
Objective Response Rate (ORR)70.9 (64.0 to 77.1)
SecondaryDuration of Response (DoR)

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).

Time frame:
RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)
Reported as:
Median · months
Duration of Response (DoR)
monthsAZD9291 80mg
Duration of Response (DoR)7.8 (1.3 to 8.4)
SecondaryDisease Control Rate (DCR)

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD (according to independent review), prior to progression (PD) or further anti-cancer therapy.

Time frame:
RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)
Reported as:
Number · % of participants
Disease Control Rate (DCR)
% of participantsAZD9291 80mg
Disease Control Rate (DCR)91.5 (86.7 to 94.9)
SecondaryProgression-Free Survival (PFS)

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.

Time frame:
RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months (at the time of analysis)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsAZD9291 80mg
Progression-Free Survival (PFS)8.6 (8.28 to 9.72)

Adverse events

Collected over AEs from start of study drug until 28 days post treatment discontinuation, up to approximately 11 months (at time of analysis).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9291 80mg—42/210 (20%)193/210 (91.9%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventAZD9291 80mg
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/210
PneumoniaInfections and infestations4/210
Supraventricular tachycardiaCardiac disorders2/210
Cerebral infarctionNervous system disorders2/210
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/210
Deep vein thrombosisVascular disorders2/210
AnaemiaBlood and lymphatic system disorders1/210
ThrombocytopeniaBlood and lymphatic system disorders1/210
Hearing impairedEar and labyrinth disorders1/210
Abdominal painGastrointestinal disorders1/210
Most frequent other events
Showing 10 of 39
Most frequent other events
EventAZD9291 80mg
DiarrhoeaGastrointestinal disorders81/210
Dry skinSkin and subcutaneous tissue disorders52/210
RashSkin and subcutaneous tissue disorders49/210
NauseaGastrointestinal disorders34/210
ConstipationGastrointestinal disorders32/210
ParonychiaInfections and infestations32/210
PruritusSkin and subcutaneous tissue disorders32/210
FatigueGeneral disorders31/210
Decreased appetiteMetabolism and nutrition disorders29/210
Back painMusculoskeletal and connective tissue disorders25/210

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD9291 80mg
Mean62.9 ± 10.91
Age, Customized
Age, Customized(Participants)AZD9291 80mg
<50 Years20
>=50-<65 Years88
>=65-<75 Years69
>=75 Years33
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291 80mg
Female146
Male64
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9291 80mg
Asian132
Black Or African American3
Native Hawaiian Or Other Pacific Islander1
Other2
White72
08

Study locations

44 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Norwalk, Connecticut 06850, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Perugia, 06132, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Akashi-shi, 673-8558, Japan
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Kitakyushu-shi, 802-0077, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Nagoya-shi, 460-0001, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Niigata-shi, 951-8566, Japan
  • Research Site
    Osaka-shi, 534-0021, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Osakasayama, 589-8511, Japan
  • Research Site
    Sakai-shi, 591-8555, Japan
  • Research Site
    Wakayama-shi, 641-8510, Japan
  • Research Site
    Yokohama-shi, 236-0051, Japan
  • Research Site
    Goyang-si, 10408, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 112, Taiwan
09

References and documents

Publications

  • Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Res Treat. 2020 Jan;52(1):284-291. doi: 10.4143/crt.2019.200. Epub 2019 Jul 23. PubMed 31345012 ↗
  • Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Janne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 Mar 15;125(6):892-901. doi: 10.1002/cncr.31891. Epub 2018 Dec 4. PubMed 30512189 ↗
  • Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crino L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Janne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820. PubMed 29293889 ↗
  • Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14. PubMed 27751847 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in May 2015, 11 months.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 11 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Mar 21, 2014
StartActual
May 20, 2014
Primary completionActual
May 1, 2015
CompletionActual
Nov 7, 2023
Results first posted
Jun 7, 2016
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02094261
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 21, 2014
Start date
May 20, 2014
Primary completion
May 1, 2015
Completion
Nov 7, 2023
Results posted
Jun 7, 2016
Last update
Nov 6, 2024

Study contacts

Glenwood Goss, MD
principal investigator · 501 Smyth Road, Ottawa, Canada
Tetsuya Mitsudomi, MD
principal investigator · Kinki University Hospital, Faculty of Medicine, Osaka, Japan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion